SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT03840915

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A Phase Ib/II, Open-Label Study of M7824 in Combination With Chemotherapy in Participants With Stage IV Non-small Cell Lung Cancer

The main purpose of the study is to evaluate the safety and tolerability of M7824 in combination with chemotherapy.

NCT03840915 Carcinoma, Non-Small-Cell Lung
MeSH:Lung Neoplasms Carcinoma, Non-Small-Cell Lung
HPO:Neoplasm of the lung Non-small cell lung carcinoma

11 Interventions

Name: Cisplatin

Description: Cisplatin will be administered intravenously at a dose of 75 milligrams per meter square (mg/m^2) over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
Type: Drug
Group Labels: 2

Cohort A: Cisplatin or Carboplatin + Pemetrexed + M7824 Cohort C: Cisplatin or Carboplatin + Gemcitabine + M7824

Name: Carboplatin

Description: Carboplatin will be administered at area under the concentration-time Curve (AUC) 5 when combined with pemetrexed over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
Type: Drug
Group Labels: 1

Cohort A: Cisplatin or Carboplatin + Pemetrexed + M7824

Name: Pemetrexed

Description: Pemetrexed will be administered intravenously at a dose of 500 mg/ m^2 over 10 minutes every 21 days.
Type: Drug
Group Labels: 1

Cohort A: Cisplatin or Carboplatin + Pemetrexed + M7824

Name: Nab-paclitaxel

Description: Nab-paclitaxel will be administered intravenously at as dose of 100 mg/m^2 over 30 minutes in a 21 days cycle on Day 1, 8, and 15 in each cycle for 4 cycles (each cycle is 21 days).
Type: Drug
Group Labels: 1

Cohort B: Carboplatin + Paclitaxel or Nab-paclitaxel + M7824

Name: Gemcitabine

Description: Gemcitabine will be administered intravenously at a dose of 1250 mg/m^2 over 30 minutes in a 21 days cycle on Day 1, and 8, in each cycle for 4 cycles (each cycle is 21 days).
Type: Drug
Group Labels: 1

Cohort C: Cisplatin or Carboplatin + Gemcitabine + M7824

Name: Docetaxel

Description: Docetaxel will be administered intravenously at a dose of 75 mg/m^2 over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
Type: Drug
Group Labels: 1

Cohort D: Docetaxel + M7824

Name: M7824

Description: M7824 will be administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 and pemetrexed.
Type: Drug
Group Labels: 1

Cohort A: Cisplatin or Carboplatin + Pemetrexed + M7824

Name: Carboplatin

Description: Carboplatin will be administered at area under the concentration-time Curve (AUC) 6 when combined with nab-paclitaxel over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
Type: Drug
Group Labels: 1

Cohort B: Carboplatin + Paclitaxel or Nab-paclitaxel + M7824

Name: Carboplatin

Description: Carboplatin will be administered at area under the concentration-time Curve (AUC) 5 when combined with gemcitabine over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
Type: Drug
Group Labels: 1

Cohort C: Cisplatin or Carboplatin + Gemcitabine + M7824

Name: M7824

Description: M7824 will be administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 alone.
Type: Drug
Group Labels: 3

Cohort B: Carboplatin + Paclitaxel or Nab-paclitaxel + M7824 Cohort C: Cisplatin or Carboplatin + Gemcitabine + M7824 Cohort D: Docetaxel + M7824

Name: Paclitaxel

Description: Paclitaxel will be administered intravenously at a dose of 200 mg/m2 over 3 hours every 3 weeks for 4 cycles (each cycle is 21 days).
Type: Drug
Group Labels: 1

Cohort B: Carboplatin + Paclitaxel or Nab-paclitaxel + M7824


Primary Outcomes

Measure: Incidence of Dose Limiting Toxicities (DLTs)

Time: Day 1 to Day 21 (Cycle 1)

Measure: Incidence of Treatment Emergent Adverse Events (TEAEs) and Treatment Related Adverse Events

Time: Up to 3 years

Secondary Outcomes

Measure: Confirmed Objective Response as Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1

Time: Up to 3 years

Measure: Progression-Free Survival (PFS) as Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1

Time: Up to 3 years

Measure: Overall Survival (OS)

Time: Up to 3 years

Measure: Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1

Time: Up to 3 years

Measure: Concentration of M7824 Observed Immediately at the End of Infusion (Ceoi)

Time: Up to 3 years

Measure: Concentration of M7824 Observed Immediately Before Next Dosing (Ctrough)

Time: Up to 3 years

Measure: Area Under the Serum Concentration-Time Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of M7824

Time: Up to 3 years

Measure: Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of M7824

Time: Up to 3 years

Measure: Maximum Observed Serum Concentration (Cmax) of M7824

Time: Up to 3 years

Measure: Time to Reach Maximum Serum Concentration (Tmax) of M7824

Time: Up to 3 years

Measure: Apparent Terminal Half-life (t1/2) of M7824

Time: Up to 3 years

Measure: Immunogenicity of M7824, as Assessed by Anti-drug Anti-body (ADA) Assay

Time: Up to 3 years

Purpose: Treatment

Allocation: Non-Randomized

Parallel Assignment


There is one SNP

SNPs


1 V600E

Fresh biopsies should be collected if archived tumor material is not available - Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at study entry and date of first dose Exclusion Criteria: - The participant's tumor harbors an epidermal growth factor receptor (EGFR) sensitizing (activating) mutation,ROS1 rearrangement, or BRAF V600E mutation or anaplastic lymphoma kinase (ALK) positive, if targeted therapy is locally approved - Mixed small cell with NSCLC cancer histology - Has received major surgery within 4 weeks prior to the first dose of study intervention; received thoracic radiation therapy (RT) of > 30 gray (Gy) within 6 months prior to the first dose of study intervention - Previous malignant disease (other than the target malignancy to be investigated in this study) within the last 3 years - Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. --- V600E ---



HPO Nodes


HPO: